Abstract:Rationale Spironolactone is a steroidal drug prescribed for a variety of medical conditions and is extensively metabolized quickly after administration. Measurement of spironolactone and its metabolites remains challenging using mass spectrometry (MS) due to in‐source fragmentation and relatively poor ionization using electrospray ionization. Therefore, improved methods of measurements are needed, particularly in the case of small sample volumes. Methods Girard's reagent P (GP) derivatization of spironolactone was employed to improve response and provide an MS‐based solution to the measurement of spironolactone and its metabolites. We performed ultra‐high‐performance liquid chromatography‐electrospray ionization‐tandem mass spectrometry (UHPLC‐ESI‐MS/MS) and ion mobility spectrometry (IMS)–high‐resolution mass spectrometry (HRMS) to fully characterize the GP derivatization products. Analytes were studied in positive ionization mode, and MS/MS was performed using nonresonance and resonance excitation collision‐induced dissociation. Results We observed the successful GP derivatization of spironolactone and its metabolites using authentic chemical standards. A signal enhancement of 1–2 orders of magnitude was observed for GP‐derivatized versions of spironolactone and its metabolites. Further, GP derivatization eliminated in‐source fragmentation. Finally, we performed GP derivatization and ultra‐high‐performance liquid chromatography–high‐resolution mass spectrometry (UHPLC–HRMS) in a small volume of murine serum (20 μL) from spironolactone‐treated and control animals and observed multiple spironolactone metabolites only in the spironolactone‐treated group. Conclusions GP derivatization was proven to have advantageous mass spectral performance (e.g., limiting in‐source fragmentation, enhancing signals, and eliminating isobaric analytes) for spironolactone and its metabolites. This work and the detailed characterization using ultra‐high‐performance liquid chromatography–high‐resolution tandem mass spectrometry (UHPLC–HRMS/MS) and IMS serve as the foundation for future developments in reaction optimization and/or quantitative assay development.

Isolation and Identification of Impurities in Spironolactone

Novel Spironolactone-Analogs As Impurities in Spironolactone

Separation and Characterization of the Polymerized Impurities in Oxacillin Sodium by 2D HPSEC and HPLC IT-TOF MS

Stereoselective synthesis of the two major metabolites of spironolactone, 3alpha- and 3beta-hydroxy-7alpha-methylthio-17alpha-pregn-4-ene-21,17-carbolactone.

Content Determination of Spironolactone Tablets by HPLC

Separation and Structure Identification of the Primary Impurity in γ-Schizandrin

Identification, Isolation, and Characterization of Impurities in Sodium Tanshinone Iia Sulfonate

Preparation and Quality Control of Compound Spironolactone Cream

Content Determination of Spironolactone Capsules by HPLC

Study on the impurities of lovastatin

Study on the Isolation and Identification of Related Substances of Azithromycin

Isolation and structure characterization of related impurities in Sodium Tanshinone IIA Sulfonate by LC/ESI-MS(n) and NMR.

Synthesis of Two New Hydroxylated Derivatives of Spironolactone by Microbial Transformation

Characterization of spironolactone and metabolites derivatized using Girard's reagent P using mass spectrometry and ion mobility spectrometry

Determination and correlation of solubility of spironolactone form II in pure solvents and binary solvent mixtures

Identification of unknown impurities in triamcinolone acetonide palmitate

Isolation Strategies and Transformation Behaviors of Spironolactone Forms

Identification and quantification of impurities in amlodipine besylate tablets

Isolation and Structural Elucidation of an Unknown Impurity in Prasugrel by Semi-Preparative Liquid Chromatography.

Isolation and Identification of Major Impurities During Synthesis of the Andrographolide Derivative AL-1

Isolation and identification of four major impurities in capreomycin sulfate.